Background and Objectives: Inflammation and nutritional status are closely associated with prognosis in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). This study compared the prognostic performance of the conventional Naples score and CRP-modified Naples score for predicting in-hospital mortality. Materials and Methods: This retrospective, single-center study included 921 patients with NSTE-ACS undergoing percutaneous coronary intervention. Multivariable logistic regression, ROC analysis, reclassification indices, restricted cubic spline analysis, and decision curve analysis were performed. Results: In-hospital mortality occurred in 79 patients (8.6%). Patients who died had higher Naples score and modified Naples score values than survivors. In multivariable models adjusted for baseline clinical variables and GRACE score, both the modified Naples score and conventional Naples score remained independently associated with in-hospital mortality. The modified Naples score showed an adjusted-OR of 3.85 (95% CI: 2.71–5.48; p < 0.001), whereas the conventional Naples score showed an adjusted-OR of 4.52 (95% CI: 3.05–6.70; p < 0.001). The addition of the modified Naples score improved model performance, with a C-index of 0.819, NRI of 0.741, and IDI of 0.127. Similarly, the conventional Naples score model showed a C-index of 0.827, NRI of 0.843, and IDI of 0.125. In ROC analysis, the AUC was 0.701 for the modified Naples score and 0.683 for the conventional Naples score, without a statistically significant difference between them (ΔAUC = 0.017; p = 0.300). Decision curve analysis showed positive net clinical benefit for both scores, with no consistent superiority of either score. Conclusions: Both Naples-based scores were independently associated with in-hospital mortality and provided comparable prognostic performance in patients with NSTE-ACS undergoing PCI.
9 September 2026 in Catheterization and Cardiovascular Interventions
Purpose: Malnutrition and inflammation are common in ST-segment elevation myocardial infarction and may influence early vulnerability. We evaluated whether the admission Geriatric Nutritional Risk Index is associated with in-hospital adverse events, and compared it with the Prognostic Nutritional Index and the Controlling Nutritional Status score.Materials and Methods: This retrospective observational study included 748 consecutive adults with the infarction treated between January 2024 and December 2025. The nutritional index was calculated from admission albumin, weight, height, and sex. The primary endpoint was a composite of in-hospital ventricular tachycardia or fibrillation, intubation, death, contrast-associated acute kidney injury, cardiogenic shock, intra-aortic balloon pump, or cardiopulmonary resuscitation; a prespecified nonrenal composite was a sensitivity endpoint. The index was modeled continuously per 10-point lower value with logistic regression and bootstrap internal validation.Results: The primary endpoint occurred in 141 of 748 patients (18.9%). Median GNRI was 98.3 (interquartile range, 95.3–102.0). Each 10-point lower GNRI was associated with the primary endpoint before adjustment (odds ratio 1.61, 95% confidence interval 1.13–2.28) and after demographic and comorbidity adjustment (1.57, 1.10–2.23). The association was attenuated after additional adjustment for acute severity (0.99, 0.66–1.49), with a similar pattern for the nonrenal composite. The areas under the receiver-operating characteristic curve were 0.579 for GNRI, 0.564 for CONUT, and 0.457 for PNI.Conclusion: A lower admission index was associated with a higher risk of in-hospital mortality; however, this association was attenuated after accounting for acute illness severity. As a simple and readily available nutritional marker at admission, the index should be used as an indicator of overall frailty rather than as a standalone decision-making tool.
Objective: Fluoroquinolones have been linked to collagen-related adverse events and aortic aneurysm or dissection, but their relationship with coronary artery ectasia (CAE) is unknown. We evaluated whether documented systemic fluoroquinolone exposure was associated with angiographically defined CAE and with CAE anatomic phenotype. Material and Methods: In this retrospective case-control study, 530 adults undergoing coronary angiography between January 2023 and May 2024 were included: 267 with CAE and 263 angiographic controls. The exposure was documented systemic fluoroquinolone use before angiography, ascertained from institutional prescribing and medication records. Logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs) with sequential adjustment for demographics, cardiovascular risk factors, angiographic indication, and other antibiotic and non-steroidal anti-inflammatory drug exposure. Cumulative dose, active-comparator, overlap-weighted, and case-only analyses were supportive. Results: Fluoroquinolone exposure was present in 152 of 267 cases (56.9%) and 71 of 263 controls (27.0%). The unadjusted OR was 3.57, 95% CI [2.48, 5.15]; the association persisted after adjustment for measured clinical and medication covariates, OR = 3.83, 95% CI [2.61, 5.62], p < .001. Among 223 exposed participants, an exploratory dose trend was detected (adjusted OR per category = 2.55, 95% CI [1.66, 3.91], p < .001). Findings were consistent in active-comparator and overlap-weighted analyses. Among cases, no statistically significant association with multivessel or diffuse Markis type I/II CAE was detected. Conclusion: Documented fluoroquinolone exposure was associated with CAE after adjustment for measured covariates; no statistically significant association with angiographic extent was detected among CAE cases. These findings are hypothesis-generating and require confirmation in multicenter, pharmacy-linked studies.